Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Shiv Kumar Sarin (shivsarin@gmail.com)
Institute of Liver and Biliary Sciences, New Delhi, India  https://orcid.org/0000-0002-0544-5610

Ashok Choudhury
Institute of Liver and Biliary Sciences, New Delhi, India

George K Lau
Humanity and Health Clinical Trial Center, Hong Kong SAR, China

Ming-Hua Zheng
the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Dong Ji
Fuyang Second People's Hospital, Fuyang, China

Sherief Abd-Elsalam
Tanta University, Egypt

Jaeseok Hwang
Keimyung University Dongsan Hospital, Daegu, South Korea

Xiaolong Qi
The First Hospital of Lanzhou University, Lanzhou, China

Ian Homer Cua
St. Luke's Medical Center- Global City, Philippines

Jeong Ill Suh
Dongguk University Gyeongju Hospital, Gyeongju, South Korea

Jun Gi Park
Dongguk University Gyeongju Hospital, Gyeongju, South Korea

Opass Putcharoen
Chulalongkorn University and Thai Red Cross, Bangkok, Thailand

Apichat Kaewdech
Prince of Songkla University, Songkhla, Thailand.

Teerha Piratvisuth
Prince of Songkla University, Songkhla, Thailand

Sombat Treeprasertsuk
Chulalongkorn University and Thai Red Cross, Bangkok, Thailand
Sooyoung Park  
Kyungpook national University hospital, Daegu, South Korea

Salisa Wejnaruemarn  
Chulalongkorn University and Thai Red Cross, Bangkok, Thailand

Diana A. Payawal  
Fatima University Medical Center, Philippines

Oidov Baatarkhuu  
Mongolian National University of Medical Sciences, Mongolia.

Sang Hoon Ahn  
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Chang Dong Yeo  
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Uzziel Romar Alonzo  
Fatima University Medical Center, Philippines

Tserendorj Chimbayar  
National Center for Communicable Diseases, Mongolia.

Imelda M. Loho  
"Dharmais" National Cancer Hospital, Jakarta, Indonesia

Osamu Yokosuka  
Chiba University, Chiba, Japan

Wasim Jafri  
Aga Khan University, Karachi, Pakistan

Soeksiam Tan  
Selayang Hospital, Malaysia

Lau Ing Soo  
Selayang Hospital, Malaysia

Tawesak Tanwandee  
Faculty of Siriraj Hospital, Mahidol University, Bangkok, Thailand

Rino Gani  
Cipto Mangunkusumo Hospital, University of Indonesia

Lovkesh Anand  
Manipal Hospital, New Delhi, India

Eslam Saber Esmail  
Tanta University, Egypt

Mai Khalaf  
Tanta University, Egypt

Shahinul Alam  
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Chun-Yu Lin
Research Article

Keywords: COVID-19, SARS CoV2, Acute Liver Injury, Chronic Liver Disease

DOI: https://doi.org/10.21203/rs.3.rs-36338/v1

License: ☕️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background and Aims:** COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon co morbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirrhosis.

**Methods:** Data was collected from 13 Asian countries on patients with CLD, known or newly diagnosed, with confirmed COVID-19.

**Result:** Altogether, 228 patients [185 CLD without cirrhosis and 43 with cirrhosis] were enrolled, with comorbidities in nearly 80%. Metabolism associated fatty liver disease (113, 61%) and viral etiology (26, 60%) were common. In CLD without cirrhosis, diabetes [57.7% vs 39.7%, OR=2.1(1.1-3.7), p=0.01] and in cirrhotics, obesity, [64.3% vs. 17.2%, OR=8.1(1.9-38.8), p=0.002) predisposed more to liver injury than those without these. Forty three percent of CLD without cirrhosis presented as acute liver injury and 20% cirrhotics presented with either acute-on-chronic liver failure [5(11.6%)] or acute decompensation [4(9%)]. Liver related complications increased (p<0.05) with stage of liver disease; a Child-Turcotte Pugh score of 9 or more at presentation predicted high mortality [AUROC-0.94, HR=19.2(95CI 2.3-163.3), p<0.001, sensitivity 85.7% and specificity 94.4%). In decompensated cirrhotics, the liver injury was progressive in 57% patients, with 43% mortality. Rising bilirubin and AST/ALT ratio predicted mortality among cirrhosis.

**Conclusions:** SARS-Cov-2 infection causes significant liver injury in CLD patients, decompensating one fifth of cirrhosis, and worsening the clinical status of the already decompensated. The CLD patients with diabetes and obesity are more vulnerable and should be closely monitored.

Introduction

The pandemic of respiratory infection with Severe Acute Respiratory Syndrome Corona Virus –2 (SARS-CoV–2) has already infected 7 million people globally, leaving 4 lacs dead. [1] SARS-CoV–2 is an enveloped, non-segmented, positive-sense RNA virus belonging to β-coronavirus family [2] and causes fever, dry cough and breathing difficulty, which can progress to respiratory distress due to interstitial pneumonia and multi-organ involvement [3,4]. The later is due to systemic inflammation leading to a cytokine storm and immune dysfunction often with features of macrophage activation syndrome, as evidenced by hyperferritinaemia, hepatic dysfunction and diffuse intravascular coagulation [5]. Viral entry is through the ACE–2 receptor; high expression of which is noted in type II alveolar cells, enterocytes, cholangiocytes, myocardial cells and proximal tubule cells of kidney, predisposing the concerned organs to the risk of developing complications [6,7].

Deranged liver functions, mainly raised alanine aminotransferase (ALT) and aspartate aminotransferase (AST), have been reported in 14–53% patients without known liver disease [8,9]. Patients with severe disease showed higher frequency and degree of liver dysfunction while in milder cases, the liver injury was transient [10]. The mechanisms of hepatic injury include immune-mediated inflammation, hypoxic
injury due to severe pneumonia and drug related [11]. It is also postulated that expression of ACE2 receptor on cholangiocytes may predispose to cholestatic injury. [12. Data on post-mortem liver biopsies is limited and demonstrates moderate microvascular steatosis and mild lobular and portal activity. [13].

The acute insult in COVID–19 is systemic and it may progress to involve other systems. Co morbidities like diabetes, hypertension, obesity, coronary artery disease and chronic liver disease (CLD) co-exist in general population, more so in middle aged and elderly [8,14]. While the true burden of liver disease is not known; these accounted for 4.6% of all deaths [15]. In fact, liver diseases contribute global disease burden in the form of metabolism associated liver disease (MAFLD), alcohol-associated liver disease and viral hepatitis [16]. Hence, during Covid–19 pandemic, it is very likely that CLD patients would be exposed to SARS-CoV–2 infection. Moreover, many cirrhosis patients are required to attend hospitals regularly and become susceptible to SARS-CoV–2 infection. Importantly, the SARS-CoV–2 infection produces lymphocytopenia with or without leukopenia, thrombocytopenia and raised fibrinogen degradation products [5,8,17], which pre-exist in CLD patients due to bone marrow suppression and cirrhosis associated immune dysfunction syndrome (CAIDS) [18].

Acute liver injury in healthy individuals has been reported in a few studies. However, the impact of SARS-Cov–2 infection on pre-existing CLD, compensated and decompensated cirrhosis is largely unknown. While in the presence of normal liver synthetic function, rise in liver enzymes with or without jaundice may be transitory and recover spontaneously. However, whether SARS-Cov–2 infection can inflict serious and prolonged liver injury in patients of CLD and may aggravate already compromised hepatic synthetic functions leading to development of acute-on-chronic liver failure (ACLF), acute decompensation (AD) in a cirrhotic liver or, worsening of prior decompensated liver disease is not known. The severity and incidence of kidney injury, secondary infections, hepatic encephalopathy, gastrointestinal bleeding and mortality, also needs to be known in a large-cohort. The Asia Pacific Association for the Study of the Liver (APASL) launched a pan-Asia collaborative study “APASL COVID Liver Injury Spectrum (APCOLIS, clinical trial identifier NCT04345640). The aim is to study the spectrum of liver injury, complications of liver disease and COVID–19 related complications in relation to pre-existing liver disease and its spectrum with SARS CoV2 infection.

Patients And Methods

Study Design

Data was collected on a web-based performa of COVID–19 patients, seen in Asia, between January to April 2020, under the APASL COVID–19 task force with the help of APASL ACLF Research Consortium (AARC) a multinational registry. Institutional ethics committee approval was obtained [NCT04345640]. All authors had access to the study data, and had the opportunity to review and approve the final manuscript.
Patients

Admitted patients with COVID–19 disease, 18 years or above, were considered for data source. Patients with known or newly diagnosed CLD or cirrhosis and infected with SARS-Cov–2 were included in the analysis. The presenting complaints, laboratory parameters, clinical events and survival outcome till day 28 were obtained. The primary objective was to determine the clinical presentation, biochemical alterations, complications and survival outcome of SARS-Cov–2 infection in the whole spectrum of CLD. The secondary objectives were to compare the pattern of liver injury in relation to existing synthetic functions, COVID–19 disease severity and influence of comorbidities. We also analyzed the predictors of severity of liver injury and influence of etiology on outcomes. The primary end point was death or complete recovery from COVID–19. Secondary end points were severity of disease, liver injury profile, complications related to liver disease and in relation to COVID–19.

Diagnosis of COVID–19- Confirmation of SARS-CoV–2 infection was achieved as per guidelines [20], with proper extraction of nucleic acids from the respiratory sample followed by RT-PCR assay for virus detection.

Treatment- Individualized antiviral or drug therapy protocol given at respective centres was collected. Generally, isolation for asymptomatic cases, hydroxychloroquine with azithromycin and antiviral drugs (oseltamivir, remdesivir, favipiravir, lopinavir+ritonavir) at admission in mild and moderate cases was practiced. The moderate and severe cases received antibiotics, convalescent plasma, steroid in form of intravenous methylprednisolone or IVIG, in case to case basis. Decisions was fluid management, vasopressors, high flow nasal cannula (HNFC) at 10L, and non-invasive or invasive ventilation were made as per standard protocols.

The liver specific treatment was considered as per the complications. The nutrition, management of HE, acute variceal bleed and ascites was similar to that for cirrhotics. Acute kidney injury (AKI) was managed initially with terlipressin and albumin, upon failure of which renal replacement therapy was considered with SLED (Sustained Low Efficiency Dialysis). Therapeutic plasmapheresis was done in a few cases with worsening jaundice, coagulopathy in absence of overt sepsis. The patients were declared cured as per the WHO test based definition. Detailed clinical data was collected during hospitalization, at discharge and till a follow up of 28 days.

Severity of COVID–19 - This was done based upon the triaging and treatment protocols [21]:

- Asymptomatic- the testing and confirmation was done only for those having contact, travel history but no symptoms.
- Mild- with fever, cough, fatigue, loose motions and other non-specific complaints.
• Severe—with severe pneumonia (i.e. SpO2 <93% despite high-flow nasal cannula O2 or respiratory rates >30 per minute), features of acute respiratory distress syndrome (ARDS), acute kidney, heart or circulatory failure, altered sensorium or combination of above.

**Acute Liver Injury (ALI)** Defined as anyone of the following – i) jaundice with a total bilirubin level of ≥3 mg/dl, ii) Acute increase in ALT, AST, SAP, GGT ≥2 times upper normal limit, iii) PT-INR of ≥1.5 with a previously normal liver parameters.

**New Onset Acute Liver Injury**- Defined as those fulfilling the above definition of ALI which developed during hospital stay, but was not there at presentation.

**Acute kidney injury**- increase in serum creatinine levels to 1.5 times of baseline or greater, within 7 days; or absolute value of ≥1.5mg/dl or urine volume of <0.5 ml/kg/h for 6 hours.

**Chronic Liver disease without Cirrhosis**- Case of chronic hepatitis B or C, MAFLD and Autoimmune Hepatitis diagnosed previously or during current admission with advanced fibrosis, by liver biopsy or transient elastography within last 6 months.

**Cirrhosis**: Patients with clinical features and imaging/endoscopy suggestive of chronic liver disease and portal hypertension or a previously diagnosed case of cirrhosis.

**Acute-on-Chronic Liver Failure (ACLF)** Acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy, in a patient with previously diagnosed or undiagnosed chronic liver disease associated with high 4 week mortality.

**Acute Decompensation (AD)**: Acute development of jaundice (bilirubin >3mg/dl), large ascites (grade ii-iii), hepatic encephalopathy, gastrointestinal hemorrhage or sepsis, or any combination of these occurring in a period of 90 days before presentation.

**Overall Complications**: The presence of AKI with or without need of renal replacement therapy, hypotension or shock, altered sensorium, respiratory distress (as defined in severe ARDS) or need of mechanical ventilation and liver related complications.

**Liver related complications**: Development of complications like worsening of jaundice (bilirubin >3mg/dl), worsening or development of new ascites, hepatic encephalopathy, acute variceal bleed and spontaneous bacterial peritonitis.

**Data collection and Statistical Analysis:**

The retrospectively collected data was analysed as groups i.e. patients having CLD without cirrhosis, those having cirrhosis with or without decompensation, those with or without acute liver injury during COVID-19 infection. Descriptive statistics were expressed as mean ±SD or median (IQR). The Student’s t-test for continuous data, Fisher’s exact test or Pearson's Chi-square test for categorical data and Kaplan-
Meier curve with long-rank test was considered for survival outcomes. AUROC was used to derive the applicability and cut-off for CTP score to predict mortality. The proportional risk between the groups was calculated as odds ratio. All statistical tests were two-tailed, and a significance level (p) of 0.05 was used. All statistical tests were performed using SPSS.

Results

We present the data obtained from 13 Asian countries and 62 investigators on the spectrum of liver injury and outcomes in CLD patients infected with SARS-CoV–2. Present study included 408 confirmed COVID–19 cases, of which 175 had no evidence of chronic liver disease and another 5 had inadequate data. (Fig–1). Altogether, 228 CLD patients were therefore included; 43(18.9%) with cirrhosis (including 18 decompensated cirrhosis) and 185 (81.1%) without cirrhosis.

Profile of patients of CLD with or without cirrhosis exposed to SARS-CoV–2 infection

The patients were mostly in the fifth or sixth decade with high rates of comorbidities. CLD without cirrhosis had male preponderance (57.8% versus 41.9%, p = 0.01) with MAFLD being more common (61.1% versus 32.5%, p = 0.003). The symptoms, laboratory parameters including leukocyte and platelet count and the severity of COVID–19 disease (18.6% versus 11.8%, p = 0.14) were comparable [Table–1].

More patients of cirrhosis had acute liver injury at admission (32.6% vs 20%, p<0.001) and also developed new onset liver injury in-hospital (39.5% versus 7%, p<0.001) those who had no ALI at presentation. The ALI occurred in 40% of those without cirrhosis, but without decompensation. The ALI caused decompensation in 20.7% of cirrhotics, 9.1% developed AD and 11.6% ACLF.

COVID–19 related complications, i.e. acute kidney injury (18.6% versus 5.4%, p<0.001), respiratory failure (23.2% versus 8.6%, p<0.001) and hypotension (14% versus 3.8%, p<0.001) were more common in cirrhotics than CLD without cirrhosis. Those with cirrhosis needed more ICU care (25.6% versus 12.4%, p<0.001), developed higher liver related complications (32.6% versus 14.1, p = 0.007) leading to higher mortality (16.3% versus 2.7%, p = 0.002).

Profile of Cirrhosis with or without decompensation exposed to SARS-CoV–2 infection

The present study had 43 cirrhosis patients; 18 (41.8%) with prior decompensation, 16 (37.2%) with Child B and 3 (9%) with Child C. Most common etiology was viral (26, 60.5%), followed by MAFLD (14, 32.6%), alcohol (2, 4.7%) and autoimmune hepatitis (1, 2.3%) [Table S1].

Severe COVID–19 disease was more common among decompensated [33.3% versus 8%, OR = 5.5 (1.1–44.3), p = 0.02] with higher complications, i.e. acute kidney injury (33.3% versus 8%, p = 0.02), respiratory
failure (50% versus 4%, \( p < 0.001 \)) and circulatory failure (27.8% versus 4%, \( p = 0.02 \)). Decompensated cirrhotics had more liver injury [71.4% versus 13.8%, OR = 6.2 (1.55–29.13), \( p < 0.001 \)] at presentation. The liver related [44.4% versus 24%, OR = 3.24 (0.88–12.5), \( p = 0.08 \)] and overall complications were more in decompensated cirrhosis with greater need for ICU care and higher mortality [OR = 11.3(1.5–288.1), \( p = 0.008 \)].

**SARS-CoV–2 infection related liver injury and outcome in CLD without cirrhosis**

The liver injury in CLD patients without cirrhosis was noted more in those with severe COVID–19 disease [18% versus 5.7%, OR = 3.76(1.38–11.8), \( p = 0.004 \)]. Patients of CLD with diabetes had higher risk [57.7% versus 39.7%, \( p = 0.01 \), OR = 2.061.14–3.73)] of liver injury. Patients with liver injury, needed more ICU admissions (20.6% versus 3.4%, \( p < 0.001 \)) with higher liver related (24.7% versus 2.3%, \( p < 0.001 \)) and overall complications [39.2% versus 6.8%, \( p < 0.001 \)]. However, the recovery, hospital stay and associated mortality were comparable among those with or without liver injury [Table–2].

**SARS-CoV–2 infection related liver injury and outcome in cirrhosis**

The acute liver injury was seen in 14 (32.6%) patients [table–3]. The age, gender or presence of diabetes were comparable, but the risk of liver injury was more with diabetes (64.3% versus 17.2%, \( p = 0.002 \)). Those with liver injury had higher CTP, MELD score and were often decompensated (55.6% versus 8%, \( p < 0.001 \)) and had also contracted more severe COVID–19 disease [42.8% versus 6.9%, OR = 9.5 (1.7–79.5)]. The COVID–19 related complications, such as renal, respiratory or circulatory failure were higher among cirrhotics with liver injury and required more ICU care (42.8% versus 3.4%, \( p = 0.001 \)) with higher mortality (42.8% versus 6.9%, \( p = 0.03 \)). The liver related complications, i.e. worsening of jaundice, ascites, hepatic encephalopathy, variceal bleed and SBP happened more with COVID–19 related liver injury irrespective of decompensation.

**Degree of liver injury over time and predictors of mortality:**

The liver injury may be evident at presentation or develop and progress during the course of infection. The AST/ALT ratio, total bilirubin and R value (ALT/ALP ratio) were helpful in predicting survival in cirrhotics (Fig S1). The non-survivors had higher AST, and an AST/ALT ratio of >1.4 [AUROC=0.95, HR = 1.4(95CI 2.5–5.4), \( p = 0.02 \)] predicted mortality among cirrhotics. The mean total bilirubin remained elevated to >9 mg/dl till death in non-survivors. They also had a low R-value \( [p = 0.02 \). The liver injury occurred more towards the end of second week or early third week in non-cirrhotics (Fig-S2), but was evident at presentation or developed in the first week in cirrhotic patients.

The mortality was comparable among non-cirrhotics and compensated cirrhosis, despite more complications, liver injury and liver related complications in the later. This underscores the concept of adequacy of available hepatic reserve for recovery. It was further substantiated by the fact that decompensated cirrhosis had nearly twice the mortality seen in compensated cirrhosis [33% vs. 16.3%,
OR = 2.5(95CI 0.7–9.4) p = 0.05]. The CTP score at presentation can predict survival in a cirrhosis [AUROC 0.94, sensitivity 86% and specificity of 94%] and a score above 8 showed high mortality (85.7%, HR = 19.2(95CI 2.3–163.3), p<0.001) [Fig–2].

Discussion

The results of this large multinational study, including a cohort of 228 patients, shows that SARS-CoV–2 infection produces acute liver injury in 43% of CLD patients without cirrhosis. Additionally, 20% of compensated cirrhosis patients develop either ACLF or acute decompensation. Liver related complications were seen in nearly half of the decompensated cirrhotics, which were of greater severity and with higher mortality.

The median age of presentation was sixth decade, but age above 60 years was not a poor prognostic factor in presence of liver disease. Comorbidities like MAFLD, obesity and diabetes were present in nearly 80% of the patients. Presence of obesity is known to increase the risk of liver injury [22]. We observed that obese cirrhotics had more acute liver injury than normal weight patients [OR 8.9 (95 CI = 1.9–38.8) p = 0.02], with higher complication rates. Also, CLD patients with diabetes had more acute liver injury [OR 2.1 (95CI = 1.1–3.73), p = 0.01]. Higher incidence of ALI has also been reported in diabetics without liver disease [23]. In the present study, MAFLD was the commonest cause for CLD without cirrhosis, whereas hepatitis B was common in cirrhotics [24]. Interestingly, alcohol was found to be a less frequent cause of CLD in Asian patients infected with SARS-Co-V2.

SARS-Co-V2 infection related injury is systemic and can be more common and severe in immunocompromised individuals [14]. Presence of CAIDS can predispose CLD patients to severe infection. [18] The acute liver injury was more common and severe in patients with decompensated cirrhosis, indicating correlation between the degree of CAIDS and synthetic functions of liver. Liver injury in COVID–19 is multifactorial. It could be due to the hypoxic injury in patients with severe pneumonia [25] or intense cytokine storm with severe infection [26], or due to the drugs used as therapeutic agents [27].

The pattern of liver injury in the CLD patients was suggestive of a dominant hepatocellular injury [28] as serum ALT levels were higher than the AST levels among non-cirrhotics. Interestingly, the liver injury pattern was different in cirrhotic patients. A rapid and early worsening of jaundice and higher AST than ALT and low R value was seen in cirrhotic patients, more so in those who did not survive. This indicates that liver injury in cirrhosis is either drug induced or hypoxia related [12, 27, 29]. There was only an insignificant rise in serum alkaline phosphatase and gamma glutamyl transferase, indicating limited virus related injury to liver due to the over expression of ACE2 on cholangiocytes. However, more histological and experimental studies are required to ascertain this.

While mild derangements in the liver functions are expected in systemic infections, the term ALI is used to differentiate more severe liver injury. We defined ALI with serum bilirubin of 3mg/dl or above and liver enzymes raised at least 2 times upper limit of normal. Similar criteria for ALI were used in COVID–19 disease earlier [5, 27]. Our study supports the concept of ALI even in patients with CLD and compensated
cirrhosis. However, its relevance for development of complications and mortality would require a larger cohort of patients with different etiologies.

A correlation between hepatic reserve and liver synthetic functions was observed in development of liver related complications from COVID–19. The liver injury occurred towards the third week in CLD patients without cirrhosis, but developed within the first week in cirrhotics. The late trend of injury in CLD without cirrhosis has also been reported recently (28). The fact that cirrhosis patients may have a more serious injury, one should be careful in the choice of anti-viral agents. We could not ascertain the role of antivirals, azithromycin and hydroxychloroquine, used in nearly a third of the patients, due to multiple mechanisms of liver injuries in cirrhotics.

Significant liver failure in the form of ACLF or acute decompensation was seen in 20% of the cirrhosis patients. This observation adds a new dimension to the existing literature on COVID–19 disease. The data indicates that non-hepatotropic infections, such as SARS CoV2, can directly precipitate a hepatic injury severe enough to cause liver failure in cirrhosis patients. [30].

The present study has the limitation of non-availability of histological data for identifying those with mild or advanced fibrosis. The COVID–19 related complications leading to liver related complications is not well known in absence of biopsy, however in the era of pandemic and the recent worsening with SARS CoV2 infection suggest a temporal association. However, this was not possible in the current state of the spreading pandemic, especially in the absence of an effective antiviral or hepato-protective agent.

In summary, pre-existing liver disease is an added risk in severe COVID–19 disease. Liver related complications, overall complications and outcomes correlate with the existing hepatic reserve. Acute liver injury is more severe and progressive in patients with decompensated cirrhosis and is associated with high mortality. Comorbidities like diabetes, obesity and MAFLD do aggravate the risk of liver injury. Hence, patients with COVID–19 disease having chronic liver disease should be properly attended to, prioritized in management and duly prognosticated. These facts assume immediate relevance as at present, liver transplant services in most countries are either on hold or are available only for acute liver failure patients.

Declarations

Authorship: SKS and AC conceptualised the research design, GL has given the critical input for designing the manuscript, AC prepared the manuscript along with the statistical analysis, rest of the authors contributed the data and suggested modification, SKS did the final proof reading and provided all the logistic support.

Disclosure: “The authors declare no conflicts of interest.”

Funding: None

Corresponding Author
Prof (Dr) Shiv K Sarin, M.D., D.M., D.Sc (Hony.)

Senior Professor, Department of Hepatology and Liver Transplant

Institute of Liver and Biliary Sciences, New Delhi, India. Pin-110070

Email : shivsarin@gmail.com

**Abbreviations**

AARC- APASL ACLF Research Consortium (AARC).

ACLF- Acute on Chronic Liver Failure

AD- Acute Decompensation

AKI- Acute Kidney Injury

ALI- Acute Liver Injury

COVID-19 - Coronavirus Disease 2019

SARS CoV2- Severe Acute Respiratory Syndrome Coronavirus 2

CAIDs- Cirrhosis Associated Immunue Dysfunction syndrome

CLD-Chronic Liver Disease

AST- Aspartate aminotransferase

ALT- Alanine aminotransferase (ALT)

SAP- Serum Alkaline Phosphatase

ACE-2- Angiotensin Converting Enzyme-2

MAFLD- Metabolic Associated Fatty Liver Disease

**References**

1. https://www.who.int/docs/default-source/coronaviruse/situation-reports/ 20200512 - covid-19-sitre-113.pdf?sfvrsn=feac3b6d_2

2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74.
3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032.

4. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. https://doi.org/10.1016/s2213-2600(20)30079-5.

5. Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shaoshang Zazhi. 2020;36(0): E005.

6. Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020. https://doi.org/10.1002/jmv.25726 [Epub ahead of print].

7. Xu, H., Zhong, L., Deng, J. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci12, 8 (2020). https://doi.org/10.1038/s41368-020-0074-x

8. Hansheng Xie, Jianming Zhao, Ningfang Lian et.al. Clinical Characteristics of Non-ICU Hospitalized Patients With Coronavirus Disease 2019 and Liver injury: A Retrospective Study. Liver Int;2020 Apr 2[Online ahead of print]

9. Zhang C, Shi L, Wang F S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, Published online March 4, 2020 https://doi.org/10.1016/S2468-1253(20)30057-1.

10. Fan Z, Chen L, Li J et.al. Clinical Features of COVID-19-Related Liver Damage . medRxiv preprint doi: https://doi.org/10.1101/2020.02.26.20026971

11. Jie Li & Jian-Gao Fan. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. J Clin Transl Hepatol, 8 (1), 13-17 2020 Mar 28; PMID: 32274341 PMCID: PMC7132021 DOI: 10.14218/JCTH.2020.00019

12. Gong Feng, Kenneth I Zheng, Qin-Qin Yan et.al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol, 8 (1), 18-24 2020 Mar 28

13. Tian, S., Xiong, Y., Liu, H. et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol (2020). https://doi.org/10.1038/s41379-020-0536-x

14. Lorenzo D'Antiga. Coronaviruses and Immunosuppressed Patients. The Facts During the Third Epidemic. Liver Transpl; 2020 Mar 20[Online ahead of print]

15. Sarin S K. "Fast, Faster, and Fastest: Science on the Run During COVID-19 Drama"."Do Not Forget the Liver" Hepatol Int . 2020 Apr 10;1-2.doi: 10.1007/s12072-020-10042-0. Online ahead of print.

16. Eslam M, Sanyal A J, George J et.al. on behalf of the International Consensus Panel . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. May 2020Volume 158, Issue 7, Pages 1999–2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312

17. Yang A P, Liu J, Tao W, Li H M. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients, International Immunopharmacology (2020), doi: https://doi.org/10.1016/j.intimp.2020.106504
18. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated Immune Dysfunction: Distinctive Features and Clinical Relevance. J Hepatol. 2014 Dec;61(6):1385-96. doi: 10.1016/j.jhep.2014.08.010. Epub 2014 Aug 15. DOI: 10.1007/s12072-020-10042-0. PMCID: PMC7145935

19. Sarin SK, Choudhury A. Acute-on-chronic Liver Failure. Curr Gastroenterol Rep. 2016 Dec;18(12):61. PMID: 27747458

20. https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117

21. World Health Organization. Clinical management of COVID-19- interim guidance. https://www.who.int/publications/i/item/clinical-management-of-covid-19

22. Stefan N, Birkenfeld A. L, Schulze M. B. et al. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol (2020). https://doi.org/10.1038/s41574-020-0364-6

23. Kumar A, Arora A, Sharma P et.al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14 (2020) 535e545

24. Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, Lau G, Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis, Journal of Hepatology (2020), doi: https://doi.org/10.1016/j.jhep.2020.03.044.

25. Zhang Y, Zheng L, Liu L et.al. Liver Impairment in COVID-19 Patients: A Retrospective Analysis of 115 Cases From a Single Center in Wuhan City, China. Liver Int:2020 Apr 2[Online ahead of print]

26. Qing Ye, Bili Wang, Jianhua Mao. The Pathogenesis and Treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020 Apr 10;S0163-4453(20)30165-1. doi: 10.1016/j.jinf.2020.03.037. Online ahead of print.

27. Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests [published online ahead of print, 2020 Apr 13]. J Hepatol 2020;S0168-8278(20)30218-X. doi:10.1016/j.jhep.2020.04.006

28. Lei F, Liu Y M, Zhou F , Qin J J, Zhang P. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. First published: 02 May 2020. https://doi.org/10.1002/hep.31301

29. Kullak-Ublick GA, Andrade RJ, Merz M, et al Drug-induced liver injury: recent advances in diagnosis and risk assessment Gut 2017;66:1154-1164

30. Sarin SK, Choudhury A, Sharma MK, et.al APASL ACLF Research Consortium (AARC) for APASL ACLF working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019 Jun 6. Hepatol Int. 2019 Jul;13(4):353-390. PMID: 31172417.

Tables

Table-1: Baseline parameters among CLD patients with or without cirrhosis exposed to SARS CoV2 infection
| Parameters                  | Cirrhosis (n=43) | CLD-No Cirrhosis (n=185) | p     |
|-----------------------------|------------------|--------------------------|-------|
| Age in years (mean±SD)      | 48.3±15.5        | 51.8±14.9                | 0.15  |
| Gender (Male, n %)          | 25(41.9)         | 107(57.8)                | 0.01  |
| Comorbidity (n, %)          | 34(79.1)         | 150(81.1)                | 0.83  |
| **Etiology of liver disease** |                  |                          |       |
| MAFLD (n, %)                | 14(32.5)         | 113(61.1)                | 0.003 |
| Viral (n, %)                | 26(60.4)         | 44(23.8)                 | 0.003 |
| Ethanol (n, %)              | 2(4.6)           | 13(7.1)                  | 0.45  |
| Others (n, %)               | 1(2.3)           | 15(8.2)                  | 0.39  |
| **Type of symptoms**        |                  |                          |       |
| Fever (n, %)                | 27(62.8)         | 107(57.8)                | 0.27  |
| Cough (n, %)                | 29(67.4)         | 102(55.1)                | 0.07  |
| Shortness of breath (n, %)  | 8(18.6)          | 38(20.5)                 | 0.08  |
| **Covid Severity**          |                  |                          |       |
| Severe                      | 8(18.6)          | 23(11.8)                 | 0.14  |
| **Laboratory Parameters**   |                  |                          |       |
| Hemoglobin mg/dl (mean±SD)  | 13.5±1.5         | 13.3±2.2                 | 0.65  |
| Total WBC10⁹/cc (mean±SD)   | 5.0±2.1          | 5.8±3.1                  | 0.17  |
| Platelet 10⁹/cc (mean±SD)   | 208.6±100.9      | 209.8±91.9               | 0.95  |
| T billirubin mg/dl (median, range) | 0.9(0.2-17.5) | 0.7(0.1-6.4)            | 0.001 |
| AST IU/L (median, range)    | 37(9-4052)       | 30(11-288)               | 0.04  |
| ALT IU/L (median, range)    | 36(12-1875)      | 30(6-258)                | 0.07  |
| SAP IU/L (median, range)    | 64(36-181)       | 67(4-256)                | 0.86  |
| GGT IU/L (median, range) | 34.5(14-352) | 31(4-644) | 0.22 |
|--------------------------|--------------|-----------|------|
| S Albumin gm/dl (mean±SD) | 3.4±0.8      | 3.9±0.6   | 0.001|
| PT-INR (mean±SD)         | 1.6±2.5      | 1.2±1.03  | 0.18 |
| Creatinine mg/ml (median, range) | 0.7(0.3-6.8) | 0.5(0.2-9.3) | 0.69 |

**Acute Liver Injury**

|                          | At admission (n, %) | New onset (n, %) | p-value |
|--------------------------|---------------------|------------------|---------|
|                          | 14(32.6)            | 17(39.5)         | <0.001  |
| New onset (n, %)         | 37 (20)             | 13 (7)           | 0.01    |

**Liver injury Profile**

|                          | Worsening decompensation (n, %) | p-value |
|--------------------------|---------------------------------|---------|
| Worsening decompensation (n, %) | 4(9.3) | 0 | 0.001 |
| ACLF (n, %)              | 5(11.6)                         | 0       | 0.01   |
| ALI (n, %)               | 16(37.2)                        | 81(43.8) | 0.03   |

**Treatment Received**

|                          | HCQs+Azathioprine(n, %) | Antiviral Drugs(n, %) | Steroid(n, %) | IVIG(n, %) | Therapeutic Plasma exchange (n, %) | Convalesent Plasma(n, %) |
|--------------------------|-------------------------|-----------------------|---------------|-----------|-----------------------------------|-------------------------|
|                          | 14(32.5)                | 48(25.9)              | 12(27.9)      | 6(13.9)   | 3(6.9)                            | 2(4.6)                  |

**COVID-19 related complications**

|                          | Respiratory Failure (n, %) | Kidney Failure (n, %) | Shock (n, %) | Need of ICU care (n, %) |
|--------------------------|----------------------------|-----------------------|-------------|-------------------------|
|                          | 10(23.2)                   | 8(18.6)               | 6(14)       | 11(25.6)                |
|                          | 16(8.6)                    | 10(5.4)               | 7(3.8)      | 23(12.4)                |
|                        | CLD without cirrhosis | Liver Injury with COVID-19 | p-value |
|------------------------|-----------------------|---------------------------|---------|
| Liver related complications (n, %) | 14(32.6)              | 26(14.1)                  | 0.007   |
| Mortality (n, %)       | 7(16.3)               | 5(2.7)                    | 0.002   |
| Hospital Stay median in days | 19(2-28)             | 19(2-28)                  | 0.98    |

Table-2: Profile of CLD without cirrhosis and liver injury with COVID-19
| Parameters                                      | Acute Liver injury (n=97) | No Acute liver injury (n=88) | p    |
|------------------------------------------------|--------------------------|-----------------------------|------|
| Age in years (mean±SD)                         | 51.7±14.7                | 51.8±15.4                   | 0.97 |
| Gender (n, %)                                  | 58(59.8)                 | 49(55.7)                    | 0.65 |
| **Presence of comorbidity**                    |                          |                             |      |
| Diabetes Melitus (n, %)                        | 56(57.7)                 | 35(39.7)                    | 0.01 |
| Obesity (n, %)                                 | 36(37.1)                 | 46(52.3)                    | 0.02 |
| Cardiovascular (n, %)                          | 20(20.6)                 | 27(30.7)                    | 0.06 |
| **Etiology of liver disease**                  |                          |                             |      |
| MAFLD (n, %)                                   | 48(55.2)                 | 55(69.6)                    | 0.03 |
| Viral Hepatitis (n, %)                         | 25(28.7)                 | 15(19)                      | 0.07 |
| Ethanol (n, %)                                 | 7(8)                     | 5(6.3)                      | 0.34 |
| **COVID-19 related complications**             |                          |                             |      |
| Respiratory Failure (n, %)                     |                          |                             |      |
| Kidney Failure (n, %)                          | 8(8.2)                   | 2(2.3)                      | 0.04 |
| Circulatory Failure (n, %)                     | 6(6.2)                   | 1(1.1)                      | 0.04 |
| **Disease Course**                             |                          |                             |      |
| Need of ICU care (n, %)                        | 20(20.6)                 | 3(3.4)                      | <0.001 |
| Liver related complication (n, %)              | 24(24.7)                 | 2(2.3)                      | <0.001 |
| Over all complication (n, %)                   | 38(39.2)                 | 6(6.8)                      | <0.001 |
| Death (n, %)                                   | 3(2.1)                   | 2(2.3)                      | 1.00 |
| Hospital Stay median in days                   | 20(2-28)                 | 17(2-28)                    | 0.07 |

Table-3: Profile of liver injury due to COVID-19 among Cirrhotics.
| Parameters                      | Acute Liver injury at admission (n=14) | No Acute Liver injury at admission (n=29) | p   |
|--------------------------------|---------------------------------------|-------------------------------------------|-----|
| Age in years (mean±SD)         | 43.9±13.8                             | 50.1±16.1                                 | 0.23|
| Gender (Male, n,%)              | 6(42.8)                               | 19(65.5)                                  | 0.21|
| **Comorbidities**               |                                       |                                           |     |
| Diabetes mellitus (n, %)        | 6(42.9)                               | 14(48.3)                                  | 0.49|
| Obesity (n, %)                  | 9(64.3)                               | 5(17.2)                                   | 0.002|
| Cardiovascular (n, %)           | 3(21.4)                               | 7(24.1)                                   | 0.84|
| **COVID Disease severity**      |                                       |                                           |     |
| Severe (n, %)                   | 6(42.8)                               | 2(6.9)                                    | 0.01|
| **Laboratory Parameters**       |                                       |                                           |     |
| Hemoglobin (mean±SD)            | 14.1±1.04                             | 13.2±1.63                                 | 0.10|
| Total WBC (mean±SD)             | 6.18±2.04                             | 4.48±1.96                                 | 0.02|
| Absolute Lymphocyte (mean±SD)   | 1.61±0.89                             | 0.99±0.67                                 | 0.07|
| Platelet (mean±SD)              | 176.8±81.7                            | 222.6±106.7                               | 0.21|
| T billirubin mg/dl (median, range)| 1.4(0.9-17.5)               | 0.6(0.2-2.8)                               | 0.04|
| AST IU/L (median, range)        | 52(17-4061)                           | 31(9-66)                                  | 0.01|
| ALT IU/L (median, range)        | 42(14-1875)                           | 35(12-76)                                 | 0.03|
| SAP IU/L (median, range)        | 78.5(36-181)                          | 64(44-121)                                | 0.07|
| GGT IU/L (median, range)        | 61(14-352)                            | 38(15-108)                                | 0.01|
| S albumin (median, range)       | 2.89±0.78                             | 3.92±0.29                                 | 0.001|
| PT-INR (median, range)          | 1.31±1.17                             | 0.64±0.47                                 | 0.02|
| Creatinine (median, range)      | 1(0.3-7.1)                            | 0.6(0.2-4.3)                               | 0.18|
| Table: Cirrhosis Disease Severity |
|----------------------------------|
| **Decompensation at presentation (n, %)** | 10(71.4) | 4(13.8) | <0.001 |
| **CTP score (mean±SD)** | 8.1±2.1 | 6.0±1.05 | 0.004 |
| **Child Pugh Class** | | | 0.02 |
| **A(n, %)** | 5(35.7) | 19(65.5) | |
| **B(n, %)** | 6(42.9) | 10(34.5) | |
| **C(n, %)** | 3(21.4) | 0 | |
| **MELD Score (mean±SD)** | 20.5±9.8 | 12.3±6.4 | 0.02 |
| **CTP score at discharge (mean±SD)** | 9.29±1.98 | 7.41±1.32 | 0.005 |

| Table: Liver Injury Profile |
|-----------------------------|
| **Acute Decompensation** | 4(28.6) | 0 | <0.001 |
| **Acute on Chronic liver Failure** | 4(28.6) | 1(3.4) | |
| **Acute Liver injury** | 4(28.6) | 12(41.4) | |
| **Not affected** | 2(14.3) | 16(55.2) | |

| Table: COVID-19 related complications |
|--------------------------------------|
| **Respiratory Failure (n, %)** | 6(42.8) | 3(10.3) | 0.04 |
| **Kidney Failure (n, %)** | 5(35.7) | 1(3.4) | 0.03 |
| **Shock (n, %)** | 6(42.8) | 2(6.8) | 0.04 |

| Table: Liver Related Complications |
|-----------------------------------|
| **Worsening jaundice (n, %)** | 5(35.7) | 5(17.2) | 0.02 |
| **Worsening Ascites (n, %)** | 5(35.7) | 5(17.2) | 0.02 |
| **Hepatic encephalopathy(n, %)** | 3(21.4) | 0 | 0.03 |
| **Acute variceal bleed (n, %)** | 3(21.4) | 1(3.4) | 0.05 |
| Disease Course                        | Count | %   | Count | %   | p     |
|--------------------------------------|-------|-----|-------|-----|-------|
| Spontaneous bacterial peritonitis    | 3     | 21.4| 0     | 0.03|       |
| Need of ICU care                     | 66    | 42.8| 1     | 3.4 | 0.001 |
| Liver related complications          | 8     | 57.1| 6     | 20.7| 0.02  |
| Over all complications               | 8     | 57.1| 6     | 20.7| 0.02  |
| Death                                | 6     | 42.9| 2     | 6.9 | 0.03  |
| Hospital Stay (median in days)       | 20    | 3-28| 16    | 2-28| 0.46  |

**Figures**
Flow diagram. Enrolment of patients and Acute Liver Injury. Acute liver injury was seen at presentation in 20% of CLD without cirrhosis, 16% of compensated and 55.6% of decompensated cirrhosis. Further acute liver injury was noted in 32.4% of those without cirrhosis and in 48% of compensated cirrhosis. Where as among the decompensated cirrhotics 27% had new onset acute liver injury.
COVID-19 and Spectrum of CLD. (A) The incidence of severe disease due to COVID-19 increases progressively among non-cirrhotics to compensated to decompensated cirrhosis (p=0.03) as the synthetic function decreased. (B) There is similar trend for acute liver injury (p=0.02). (C) The mortality increased with SARS CoV2 infection significantly among cirrhotics than those without cirrhosis (p<0.001) and with decompensation. The mortality is highest (43%) in the spectrum with onset of liver injury. (D) Among cirrhosis those exposed to SARS CoV2 infection, the outcome is poor with CTP score above 8 [AUROC 0.94, sensitivity 86% and specificity of 94%, HR=19.2(95CI 2.3-163.3), p<0.001]

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- AppendixAPASLCOVIDTaskforce.docx
- Supplimentarymaterial.docx
• Highlightskeypoints.docx
• FigS1A.jpg
• FigS1B.jpg
• FigS1C.jpg
• FigS2.jpg